
Manas AI leverages proprietary AI, generative computational chemistry, and advanced biology to significantly reduce the time and costs associated with traditional drug discovery. The company focuses on developing treatments for aggressive cancers and rare diseases, utilizing a partnership with Microsoft to enhance its computational capabilities. With initiatives like Project Cosmos, Manas AI aims to revolutionize the drug development process, making it faster and more efficient, ultimately bringing life-saving treatments to patients sooner.

Manas AI leverages proprietary AI, generative computational chemistry, and advanced biology to significantly reduce the time and costs associated with traditional drug discovery. The company focuses on developing treatments for aggressive cancers and rare diseases, utilizing a partnership with Microsoft to enhance its computational capabilities. With initiatives like Project Cosmos, Manas AI aims to revolutionize the drug development process, making it faster and more efficient, ultimately bringing life-saving treatments to patients sooner.
Vertical: AI-native biopharmaceuticals (drug discovery)
HQ: New York City, NY
Founders: Dr. Siddhartha Mukherjee, Reid Hoffman, Ujjwal Singh
Latest disclosed funding: Seed (Jan 27, 2025), ~$24.6M
Employee count: 17
Drug discovery and development inefficiencies in oncology and rare disease therapeutics.
2025
Biotechnology
24.6M
Reported round size ~$24.6M (seed extension reporting).
“Includes prominent technology and VC investors (Reid Hoffman, General Catalyst, Greylock, Mosaic Ventures, The General Partnership, Wisdom Ventures, Westbound Equity Partners, Blitzscaling Ventures)”